Get 40% Off
☕ Buy the dip? After losing 17%, Starbucks sees an estimated 20% upside. See the top Undervalued stocks!Unlock list

Europe's STOXX 600 jumps 1% after ECB rate decision; Novo Nordisk hits record high

Published 07/03/2024, 08:31
Updated 07/03/2024, 17:18
© Reuters. The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, March 6, 2024.     REUTERS/Staff

By Ankika Biswas and Shubham Batra

(Reuters) -Europe's main index leapt on Thursday, after the European Central Bank kept rates steady on signs of cooling inflation and as Novo Nordisk (CSE:NOVOb) hit a record peak on encouraging trial data of its experimental obesity drug.

The pan-European STOXX 600 hit an all-time high, closing 1.1% higher, with the rate-sensitive technology sector climbing 2.3% to a December 2000 peak.

Reflecting upbeat sentiment across major blocs were benchmark indexes in Germany, France, Italy and Spain scaling all-time highs.

Euro area bond yields also fell, with markets pricing in more than 100 basis points of rate cuts in 2024 from 92 bps before the decision.

Leaving interest rates unchanged at 4.0%, the ECB tweaked its messaging slightly to reflect falling inflation over the past 1-1/2 years and new, lower economic projections.

"Equities responded to the lower inflation projections, but people also wanted to hear (ECB chief Christine) Lagarde say that the ECB was open to cutting rates as early as April, if the data supported, but she was very adamant about the need to wait until June," said Thierry Wizman, global FX and rates strategist at Macquarie.

"The ECB significantly reduced the 2024 inflation projection. Symbolically important was the 2025 reduction, which implies that the 2% inflation target will be reached by next year."

Most market participants expect the ECB will kick off policy easing among major central banks, with the Federal Reserve widely seen cutting in June.

The STOXX 600 has rallied this year, holding bumper gains from 2023, aided by somewhat resilient earnings and early rate-cut hopes. Tech stocks have been at the forefront of a buying spree as AI euphoria continues.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Novo Nordisk soared 8.3% after early trial data for its experimental obesity drug amycretin showed a higher weight loss compared with its popular Wegovy treatment.

The healthcare sector rose 2.3%, with Denmark-based Zealand Pharma, which saw BTIG initiate coverage with a "buy" rating, climbing 9.3%.

Virgin Money (LON:VMUK) UK surged 35% on Britain's Nationwide Building Society (LON:NBS)'s buyout plans in a potential 2.9 billion pound all-cash deal.

HSBC (LON:HSBA) lost 3.5% on trading ex-dividend. Further, global banking regulators proposed measures to crack down on "unacceptable" attempts by the biggest banks to game rules in a bid to avoid heavier capital requirements.

Telecom Italia (BIT:TLIT) plunged 23.8% after unveiling a three-year outlook under a new structure stemming from its planned network sale, with analysts citing enduring concerns over the debt level.

Call-centre operator Teleperformance slumped 23.1% after forecasting limited 2024 growth.

German fashion house Hugo Boss dropped 13.8% after warning of much slower sales growth this year and forecasting downbeat profit.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.